Our study represents the pioneering network meta-analysis (NMA) to evaluate both direct and indirect impacts of various doses of daprodustat, recombinant human erythropoietin (rhEPO), and placebo on anemia in dialysis-dependent chronic kidney disease (CKD) patients. This evidence concerns the gene EPO and anemia (phenotype).